AGN Neuro

Algernon Pharmaceuticals’ (OTCQB: AGNPF) wholly-owned Algernon NeuroScience (AGN Neuro) successfully completed dosing the third and final cohort of its Phase 1 clinical study assessing an intravenous (IV) formulation of the company’s DMT compound, AP-188, aiming to treat both stroke and...

Biopharma company Algernon Pharmaceuticals (OTCQB: AGNPF) has launched a new clinical research program via a subsidiary. The goal is to treat Traumatic Brain Injury (TBI) with the company’s proprietary DMT compound AP-188.  Algernon NeuroScience, or AGN Neuro, has an ongoing stroke...

The psychedelics space is up and running. Together with the start of the new year, two companies have shared their latest financial decisions toward advancing their medical business programs. Blackhawk’s New Arrangement Plan For Three Of Its Businesses Investment holding company Blackhawk...